Elanco Animal Health Incorporated (NYSE:ELAN) Receives $15.17 Consensus PT from Analysts

Elanco Animal Health Incorporated (NYSE:ELAN - Get Free Report) has earned a consensus rating of "Hold" from the seven research firms that are currently covering the company, MarketBeat.com reports. Four analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average 1-year target price among analysts that have covered the stock in the last year is $15.17.

ELAN has been the subject of a number of analyst reports. Stifel Nicolaus increased their price target on Elanco Animal Health from $15.00 to $16.00 and gave the stock a "buy" rating in a research note on Monday, May 19th. Morgan Stanley cut their price target on Elanco Animal Health from $14.00 to $13.00 and set an "equal weight" rating for the company in a research note on Wednesday, February 26th. Barclays cut their price target on Elanco Animal Health from $20.00 to $19.00 and set an "overweight" rating for the company in a research note on Wednesday, February 26th. Piper Sandler cut their price target on Elanco Animal Health from $16.00 to $12.00 and set a "neutral" rating for the company in a research note on Thursday, March 6th. Finally, UBS Group cut their price target on Elanco Animal Health from $18.00 to $17.00 and set a "buy" rating for the company in a research note on Wednesday, February 26th.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. HighTower Advisors LLC boosted its holdings in shares of Elanco Animal Health by 7.0% during the 1st quarter. HighTower Advisors LLC now owns 12,445 shares of the company's stock valued at $131,000 after purchasing an additional 810 shares during the last quarter. Hillsdale Investment Management Inc. boosted its holdings in shares of Elanco Animal Health by 2.1% during the 4th quarter. Hillsdale Investment Management Inc. now owns 43,300 shares of the company's stock valued at $524,000 after purchasing an additional 900 shares during the last quarter. Arizona State Retirement System boosted its holdings in shares of Elanco Animal Health by 0.8% during the 4th quarter. Arizona State Retirement System now owns 143,462 shares of the company's stock valued at $1,737,000 after purchasing an additional 1,166 shares during the last quarter. MTM Investment Management LLC boosted its holdings in shares of Elanco Animal Health by 9.3% during the 4th quarter. MTM Investment Management LLC now owns 14,168 shares of the company's stock valued at $172,000 after purchasing an additional 1,200 shares during the last quarter. Finally, Graypoint LLC boosted its holdings in shares of Elanco Animal Health by 4.9% during the 1st quarter. Graypoint LLC now owns 26,845 shares of the company's stock valued at $282,000 after purchasing an additional 1,256 shares during the last quarter. Institutional investors own 97.48% of the company's stock.

Elanco Animal Health Stock Performance

Shares of NYSE:ELAN traded down $0.05 during midday trading on Monday, hitting $14.25. The company had a trading volume of 4,420,428 shares, compared to its average volume of 5,180,486. The company has a debt-to-equity ratio of 0.66, a current ratio of 2.55 and a quick ratio of 1.31. The company has a market cap of $7.08 billion, a price-to-earnings ratio of 35.63, a PEG ratio of 2.50 and a beta of 1.67. Elanco Animal Health has a 12-month low of $8.02 and a 12-month high of $18.80. The company has a fifty day moving average of $11.16 and a two-hundred day moving average of $11.44.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The company reported $0.37 EPS for the quarter, topping the consensus estimate of $0.31 by $0.06. The firm had revenue of $1.19 billion during the quarter, compared to analyst estimates of $1.17 billion. Elanco Animal Health had a return on equity of 6.78% and a net margin of 4.60%. Elanco Animal Health's revenue was down 1.0% on a year-over-year basis. During the same period in the prior year, the business posted $0.34 EPS. On average, equities research analysts expect that Elanco Animal Health will post 0.91 EPS for the current fiscal year.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.